Kiladjian, Jean-Jacques
Guglielmelli, Paola
Griesshammer, Martin
Saydam, Guray
Masszi, Tamas
Durrant, Simon
Passamonti, Francesco
Jones, Mark
Zhen, Huiling
Li, Jingjin
Gadbaw, Brian
Perez Ronco, Julian
Khan, Mahmudul
Verstovsek, Srdan
Funding for this research was provided by:
Novartis (CH); Novartis Pharmaceuticals Corporation (Not applicable)
Article History
Received: 18 December 2017
Accepted: 20 December 2017
First Online: 2 February 2018
Compliance with ethical standards
:
: JJK reports grants and personal fees from Novartis, grants and personal fees from AOP Orphan, during the conduct of the study; personal fees from Shire, outside the submitted work. PG has nothing to disclose. MG participated in speaker bureau and advisory boards for Novartis, Shire, and AOP Orphan, outside the submitted work. GS received research funding from Novartis, participated in speaker bureau for Novartis, and received honoraria from Novartis, Celgene, Bristol-Myers Squibb, and Gilead, outside the submitted work. TM served as a consultant for Takeda, Novartis, Bristol-Myers Squibb, and Janssen Cilag, outside the submitted work. SD has nothing to disclose. FP participated in speaker bureau and advisory board for Novartis. MJ and HZ are employees of Incyte Corporation and own stocks of company. JL, BG, JPR, and MK are employees of Novartis. JL, MK and BG own stocks of company. SV participated in advisory boards for Novartis and Incyte.Ethics approval and consent to participateThis study was approved by the institutional review board (IRB). Each investigator site IRB approved the respective protocols. Informed consent was obtained from all patients for being included in the study.